This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Southern, J.
Right arrow Articles by Miller, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Southern, J.
Right arrow Articles by Miller, E.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, November 2004, p. 1100-1104, Vol. 11, No. 6
1071-412X/04/$08.00+0     DOI: 10.1128/CDLI.11.6.1100-1104.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Effects of Prior Polysaccharide Vaccination on Magnitude, Duration, and Quality of Immune Responses to and Safety Profile of a Meningococcal Serogroup C Tetanus Toxoid Conjugate Vaccination in Adults

Jo Southern,1* Sarah Deane,2 Lindsey Ashton,3 Ray Borrow,2 David Goldblatt,3 Nick Andrews,1 Paul Balmer,2 Rhonwen Morris,4 J. Simon Kroll,5 and Elizabeth Miller1

Immunisation Department, Communicable Disease Surveillance Centre, Health Protection Agency,1 Immunobiology Unit, Institute of Child Health,3 Imperial College London and St Mary's Hospital, London,5 Meningococcal Reference Unit, Health Protection Agency, Manchester,2 Vaccine Evaluation Unit, Health Protection Agency, Gloucester, United Kingdom4

Received 28 May 2004/ Returned for modification 21 July 2004/ Accepted 26 August 2004

Extensive use of meningococcal AC polysaccharide (MACP) vaccines has raised concerns about induction of immunologic hyporesponsiveness to C polysaccharide. We investigated the immunogenicity and safety of a meningococcal C-tetanus conjugate (MCC-TT) vaccine in naïve adults and prior MACP vaccinees. Laboratory staff (n = 113) were recruited; 73 were naïve to meningococcal vaccination, and 40 had previously received ≥1 dose of MACP vaccine. Blood was taken prior to MCC-TT vaccination and 1 week, 1 month, and 6 months later. At each time point, proportions of subjects with serum bactericidal antibody (SBA) titers of ≥8 or ≥128 were similar (P > 0.46); >94% of subjects achieved titers of ≥128 at 1 month. However, the geometric mean titer (GMT) of SBA at 1 month was higher in the naïve (1,757; 95% confidence interval [95% CI], 1,102 to 2,803) than in the previously vaccinated (662; 95% CI, 363 to 1,207) group (P = 0.02), and similarly at 6 months (P < 0.001). Conversely, geometric mean concentrations (GMCs) of serogroup C-specific immunoglobulin G (IgG) were significantly higher in the previously vaccinated group pre-MCC-TT and at 1 week; the groups were similar at 1 month, and there was some evidence that the GMC for the previously vaccinated group was higher at 6 months. Qualitative differences in antibodies between groups were demonstrated by using the SBA/IgG ratio, though avidity measures were similar for the two groups throughout the study. MCC-TT was well tolerated, with similar safety profiles in the two groups. Pain in the arm and headache were the most frequently reported events following vaccination. The study shows that MCC-TT is safe and immunogenic in naïve and previously MACP-vaccinated adults, though the magnitude and persistence of postvaccination SBA responses in the latter group were lower.

* Corresponding author. Mailing address: Immunisation Department, Communicable Disease Surveillance Centre, Health Protection Agency, 61 Colindale Ave., Colindale, London, United Kingdom. Phone: 44 (0) 208 200 6868. Fax: 44 (0) 208 200 7868. E-mail: jo.southern{at}hpa.org.uk.

Clinical and Diagnostic Laboratory Immunology, November 2004, p. 1100-1104, Vol. 11, No. 6
1071-412X/04/$08.00+0     DOI: 10.1128/CDLI.11.6.1100-1104.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Keyserling, H., Papa, T., Koranyi, K., Ryall, R., Bassily, E., Bybel, M. J., Sullivan, K., Gilmet, G., Reinhardt, A. (2005). Safety, Immunogenicity, and Immune Memory of a Novel Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (MCV-4) in Healthy Adolescents. Arch Pediatr Adolesc Med 159: 907-913 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»